PDE11A是原发性双侧大结节性肾上腺增生症的表型调节因子:334例患者系列研究结果
该研究对来自欧洲和美洲的354例原发性双侧大结节性肾上腺增生症(PBMAH)先证者进行ARMC5和PDE11A基因测序,并分析其中334例患者的表型特征。结果显示,PDE11A损害性变异携带者的尿游离皮质醇、午夜血浆皮质醇及肾上腺结节数量均低于PDE11A野生型患者,提示PDE11A损害性变异与PBMAH的衰减型表型相关。
要点
- 11.4%的PBMAH患者携带PDE11A损害性变异,19.2%携带ARMC5致病性变异。
- PDE11A损害性变异携带者尿游离皮质醇为正常上限的0.7倍,低于野生型的1.25倍(P=0.0002)。
- PDE11A损害性变异携带者肾上腺结节数为3.46个,少于野生型的4.74个(P=0.048)。
核心结论
- PDE11A似乎是PBMAH表型的调节因子,其损害性变异与衰减型表型相关,可能 contribute to PBMAH的异质性并影响患者管理。
研究设计与样本
- 对来自欧洲和美洲的354例PBMAH先证者的白细胞DNA进行ARMC5和PDE11A基因二代测序,并分析其中334例患者的表型特征以研究基因型/表型相关性。
主要发现
- 16个PDE11A变异中7个被in silico预测为损害性:6个错义变异(p.Tyr727Cys、p.Met623Arg、p.Tyr658Cys、p.Ag867Trp、p.Asn298Ser、p.Glu840Lys)和1个终止增益变异(p.Arg307Ter)。
- 队列中11.4%的患者携带上述损害性变异,19.2%携带ARMC5致病性变异。
- PDE11A损害性变异在ARMC5状态间的分布无统计学显著差异(P=0.83;OR=0.79;95%CI 0.26-2.03),ARMC5致病性变异在PDE11A状态间的分布亦无统计学显著差异(P=0.83;OR=0.81;95%CI 0.27-2.04)。
- 与PDE11A野生型患者相比,PDE11A损害性变异携带者的尿游离皮质醇较低(0.7 vs 1.25倍正常上限;P=0.0002),午夜血浆皮质醇较低(157.81 vs 222.19 nmol/L,P=0.016),肾上腺结节数量较少(3.46 vs 4.74;P=0.048)。
- 携带ARMC5致病性变异的患者表型更严重,合并症更频繁,且更多接受肾上腺切除术(60%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Primary bilateral macronodular adrenal hyperplasia (PBMAH), the most common cause of Cushing syndrome due to bilateral nodules, is a heterogeneous disease at the clinical, hormonal, and morphological levels. ARMC5-inactivating pathogenic variants are causative of PBMAH, and rare variants of PDE11A have been associated with PBMAH. OBJECTIVE: The aim of this study, on a large cohort of individuals with PBMAH from Europe and America, was to study the ARMC5 and PDE11A genotype to determine the genotype/phenotype correlation and to investigate the hypothesis that PDE11A could be a modifying gene of the adrenal phenotype. METHODS: Leukocyte DNA of 354 PBMAH index cases was sequenced for ARMC5 and PDE11A genes by next-generation sequencing. Phenotypic characteristics of 334 of these patients were analyzed to study the genotype/phenotype correlations. RESULTS: Seven out of 16 PDE11A variants were considered damaging according to in silico predictions: 6 missense variants (p.Tyr727Cys, p.Met623Arg, p.Tyr658Cys, p.Ag867Trp, p.Asn298Ser, p.Glu840Lys) and 1 stop-gain variant (p.Arg307Ter). In the cohort, 11.4% of patients had one of these variants and 19.2% had ARMC5-pathogenic variants. There was no statistically significant difference in the distribution of PDE11A-damaging variants according to ARMC5 status (P = .83; OR = 0.79; 95% CI, 0.26-2.03) nor in the distribution of ARMC5 pathogenic variants according to PDE11A status (P = .83; OR = 0.81; 95% CI, 0.27-2.04). Patients with PDE11A-damaging variants had lower urinary free cortisol (0.7 vs 1.25 upper limit of normal; P = .0002), midnight plasma cortisol (157.81 vs 222.19 nmol/L, P = .016), and number of adrenal nodules (3.46 vs 4.74; P = .048) compared to PDE11A wild-type patients. Patients with ARMC5-pathogenic variants had a more severe phenotype with more frequent comorbidities and were more often treated by adrenalectomy (60%). CONCLUSION: PDE11A appears to be a modulator of PBMAH phenotype, damaging variants being associated with an attenuated form. This may contribute to the heterogeneity of PBMAH and could affect patient management.
引用
- Vaduva P, Bouys L, Jouinot A, et al. PDE11A Is a Phenotype Modulator of Primary Bilateral Macronodular Adrenal Hyperplasia: Results of a 334-Patient Series. J Clin Endocrinol Metab. 2025. PMID: 39774659. doi:10.1210/clinem/dgae918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。